Mesalamine (Asacol, Pentasa, Apriso, Lialda, Canasa, Rowasa)
Other Medications · Approved since 1987
Description
Mesalamine is an anti-inflammatory aminosalicylate primarily approved for inflammatory bowel disease that is being evaluated for colorectal cancer prevention and immunotherapy-related colitis management. In colorectal cancer care, mesalamine serves two distinct roles: as a chemopreventive agent in Lynch syndrome patients at high risk for developing colorectal cancer, and as prophylactic therapy to prevent immune-mediated colitis in patients receiving checkpoint inhibitor combinations like ipilimumab and nivolumab. The drug's anti-inflammatory properties make it valuable for managing gastrointestinal complications associated with cancer immunotherapy.
Mechanism of Action
Mesalamine acts locally in the gastrointestinal tract by inhibiting cyclooxygenase and lipoxygenase pathways, reducing prostaglandin E2 and leukotriene B4 production. It also inhibits nuclear factor-kappa B (NF- B) activation and reduces pro-inflammatory cytokine release, while promoting anti-inflammatory mediators in the colonic mucosa.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Asacol, Pentasa, Apriso, Lialda, Canasa, Rowasa |
| Category | Other Medications |
 Status | Off-label |
| Administration | Oral |
| Year Approved | 1987 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.